Drug intelligence / Profile preview

Shenwu Capsule

Development stage: Phase 3
Lead developer: Yuekang Pharmaceutical Group
Administration: Oral

Overview

Shenwu Capsule is a traditional Chinese herbal medicine (TCM) developed by North China Pharmaceutical, primarily indicated for the treatment of amnestic mild cognitive impairment (MCI). The formulation is intended to improve cognitive function, memory, and daily living activities in elderly patients who are at an increased risk of progressing to Alzheimer's disease. As a botanical product, it likely contains multiple active ingredients that work synergistically to provide neuroprotective effects. It has undergone Phase III clinical evaluation in China to establish its efficacy and safety as a relatively simple and inexpensive treatment strategy for age-related cognitive decline.

Brand names: Shenwu Capsule
Other names: Shenwu Jiaonang

Beyond the preview

Go deeper on Shenwu Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenwu Capsule.

Explore the full profile